EMVision raises $9.0m after brain scanner successfully distinguishes stroke types in clinical trial

EMVision Medical Devices (ASX: EMV)

EMVision Medical Devices (ASX: EMV) has successfully closed a $9.0m capital raising via a share placement at $1.42 led by Bell Potter Securities. There was strong demand from both domestic and offshore institutions and wholesale investors, with bids covering the proposed placement amount multiple times. EMVision has become one of the top-performing ASX IPOs in recent years.

The funds will bolster EMVision’s balance sheet to advance development of their potentially life-saving brain scanner. The compact and transportable device aims to allow for rapid detection and monitoring of stroke in hospitals. Future generations of the device plan to provide ultra-early stroke type detection in ambulances.
Earlier this week, EMVision released preliminary images from its ongoing clinical trial showing the device can successfully detect haemorrhagic (bleeds), and in a small patient cohort, distinguish between the two stroke types (clots and bleeds).
EMVision Managing Director and CEO Dr Ron Weinberger
/Public Release.